← boardnext 2026-10-09
TECX
Tectonic Therapeuticdistress 0/10 · well-funded / low risk$31.21-1%today-18% from 52w high
Lead: PH-HFpEF
Revenue
pre-revenue
Liquidity
$237M
Runway
3.6 yrs
Shares 1y
+1%
Price & events
+63.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.2%
1D
+1.8%
1W
+2.0%
1M
+9.7%
3M
+54.8%
6M
+36.2%
1Y
+89.8%
2Y
-65.6%
5Y
-82.1%
All
Overview
- Market Cap
- $588.91M
- Volume
- 5.16K
- 52 Week Range
- $14.71 – $37.93
- Total Shares
- 18.87M
- Float Shares
- 11.23M
- Short %
- 23.77%
- % Held by Insiders
- 39.34%
- % Held by Institutions
- 74.11%
- RVOL
- 0.03x
- Beta
- 0.10
Pipeline stages · 1 programs
TX000045- Dose A, TX000045- Dose B
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10-09 Estimated 50% readout ~2026-11-23 | Phase 2 | TX000045- Dose A, TX000045- Dose B | Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction | — | recruiting |
Catalyst news & presentations · 14
- late Q4 2026 / early Q1 2027Guided 70%trial initiationsecondaryPhase 2TX2100 · Phase 2 trial plannedSEC 8-K
- early Q1 2027Guided 70%readoutPhase 2TX45 · Topline results from APEX Phase 2 trial expected.SEC 8-K
- 2026Guided 40%readoutPhase 2TX45 · Topline results from APEX Phase 2 trialSEC 8-K
- 2026Guided 40%trial initiationsecondaryPhase 2TX45 · Phase 2 trial to evaluate safety and hemodynamic effectsSEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- June 10, 2026enrollment completesecondaryPhase 2TX45 · Completed enrollment in APEX Phase 2 trial for PH-HFpEF.SEC 8-K
- Q4 2025 / Q1 2026trial initiationsecondaryPhase 1TX2100 · Phase 1 trial initiationSEC 8-K
- early Q4 2025readoutPhase 1TX45 · Topline results from Part B of Phase 1b trialSEC 8-K
- mid-2025readoutPhase 1TX45 · Topline results of Phase 1b hemodynamic trialSEC 8-K
- Q1 2025readoutPhase 1TX45 · Phase 1b topline hemodynamic results in PH-HFpEF subjects (Part A)SEC 8-K
- November 2024conferencedata presentationsecondaryTX45 · Full Phase 1a results to be presented at AHA Scientific Sessions.SEC 8-K
- third quarter of 2024trial initiationsecondaryPhase 2TX45 · Initiation of global Phase 2 trialSEC 8-K
- September 2024readoutPhase 1TX45 · Topline results of Phase 1a single ascending dose trialSEC 8-K
- 2024-09-19fda agreementTX45 · FDA cleared Investigational New Drug (IND) application for TX45 (announced previously, referenced here).SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $78 (+151% upside) · 9 analysts
- 2026-05-26Raymond JamesOutperform → Strong Buy
- 2026-04-14StifelBuy
- 2026-01-08Truist SecuritiesBuy
- 2025-09-03OppenheimerOutperform
- 2025-07-21Truist SecuritiesBuy
- 2025-06-06LifeSci CapitalOutperform
Competitors — PH-HFpEF
- TENXTENAX THERAPEUTICS, INC.$390M · D2
Recent news
- 2026-07-13TECX Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues R&D Investment - Net Income Trends - dars.gov.et
- 2026-07-13Enterprise value to revenue forward of Tectonic Therapeutic, Inc. – BOATS:TECX - TradingView
- 2026-07-09Here's Why We're Not Too Worried About Tectonic Therapeutic's (NASDAQ:TECX) Cash Burn Situation - Moomoo
- 2026-07-09We're Hopeful That Tectonic Therapeutic (NASDAQ:TECX) Will Use Its Cash Wisely - simplywall.st
- 2026-07-09We're Hopeful That Tectonic Therapeutic (NASDAQ:TECX) Will Use Its Cash Wisely - Sahm
- 2026-07-04If You Invested $1,000 in Tectonic Therapeutic Inc (TECX) - Stock Titan
- 2026-07-02$TECX stock is up 11% today. Here's what we see in our data. - Quiver Quantitative
- 2026-07-01Tectonic Therapeutic (TECX) CSO exercises options and sells 172 shares under 10b5-1 plan - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.